Interferon-omega: Current status in clinical applications

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Since 1985, interferon (IFN)-ω, a type I IFN, has been identified in many animals, but not canines and mice. It has been demonstrated to have antiviral, anti-proliferation, and antitumor activities that are similar to those of IFN-α. To date, IFN-ω has been explored as a treatment option for some diseases or viral infections in humans and other animals. Studies have revealed that human IFN-ω displays antitumor activities in some models of human cancer cells and that it can be used to diagnose some diseases. While recombinant feline IFN-ω has been licensed in several countries for treating canine parvovirus, feline leukemia virus, and feline immunodeficiency virus infections, it also exhibits a certain efficacy when used to treat other viral infections or diseases. This review examines the known biological activity of IFN-ω and its clinical applications. We expect that the information provided in this review will stimulate further studies of IFN-ω as a therapeutic agent.

Highlights

•

Few systemically review about interferon omega is online.
•

We provide a broad knowledge of the characteristics and biological functions of IFN-ω.
•

We examine the known information of IFN-ω which used as potential application in treating some diseases or virus.

Related collections

Most cited references 92

Record: found
Abstract: found
Article: not found

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Sergei V. Kotenko, Grant Gallagher, Vitaliy V Baurin … (2003)

We report here the identification of a ligand-receptor system that, upon engagement, leads to the establishment of an antiviral state. Three closely positioned genes on human chromosome 19 encode distinct but paralogous proteins, which we designate interferon-lambda1 (IFN-lambda1), IFN-lambda2 and IFN-lambda3 (tentatively designated as IL-29, IL-28A and IL-28B, respectively, by HUGO). The expression of IFN-lambda mRNAs was inducible by viral infection in several cell lines. We identified a distinct receptor complex that is utilized by all three IFN-lambda proteins for signaling and is composed of two subunits, a receptor designated CRF2-12 (also designated as IFN-lambdaR1) and a second subunit, CRF2-4 (also known as IL-10R2). Both receptor chains are constitutively expressed on a wide variety of human cell lines and tissues and signal through the Jak-STAT (Janus kinases-signal transducers and activators of transcription) pathway. This receptor-ligand system may contribute to antiviral or other defenses by a mechanism similar to, but independent of, type I IFNs.

0 comments Cited 570 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

IL-28, IL-29 and their class II cytokine receptor IL-28R.

Paul Sheppard, Wayne Kindsvogel, Wenfeng Xu … (2003)

Cytokines play a critical role in modulating the innate and adaptive immune systems. Here, we have identified from the human genomic sequence a family of three cytokines, designated interleukin 28A (IL-28A), IL-28B and IL-29, that are distantly related to type I interferons (IFNs) and the IL-10 family. We found that like type I IFNs, IL-28 and IL-29 were induced by viral infection and showed antiviral activity. However, IL-28 and IL-29 interacted with a heterodimeric class II cytokine receptor that consisted of IL-10 receptor beta (IL-10Rbeta) and an orphan class II receptor chain, designated IL-28Ralpha. This newly described cytokine family may serve as an alternative to type I IFNs in providing immunity to viral infection.

0 comments Cited 460 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Hector Ho, J Yamamoto, M Wiktor … (1987)

A highly T-lymphotropic virus was isolated from cats in a cattery in which all the animals were seronegative for feline leukemia virus. A number of cats in one pen had died and several had an immunodeficiency-like syndrome. Only 1 of 18 normal cats in the cattery showed serologic evidence of infection with this new virus, whereas 10 of 25 cats with signs of ill health were seropositive for the virus. Tentatively designated feline T-lymphotropic lentivirus, this new feline retrovirus appears to be antigenically distinct from human immunodeficiency virus. There is no evidence for cat-to-human transmission of the agent. Kittens experimentally infected by way of blood or plasma from naturally infected animals developed generalized lymphadenopathy several weeks later, became transiently febrile and leukopenic, and continued to show a generalized lymphadenopathy 5 months after infection.

0 comments Cited 132 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Fu-rong Zhao

Hui-yun Chang

Journal

Journal ID (nlm-ta): Int Immunopharmacol

Journal ID (iso-abbrev): Int. Immunopharmacol

Title: International Immunopharmacology

Publisher: Published by Elsevier B.V.

ISSN (Print): 1567-5769

ISSN (Electronic): 1878-1705

Publication date PMC-release: 12 October 2017

Publication date (Print): November 2017

Publication date (Electronic): 12 October 2017

Volume: 52

Pages: 253-260

Affiliations

State Key Laboratory of Veterinary Etiological Biology, OIE/National Foot-and-Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, Gansu, China.

Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, Jiangsu Province 225009, China.

Author notes

[* ]Corresponding authors at: Stake Key Laboratory of Veterinary Etiological Biology, National Foot-and-Mouth Diseases Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China. zhaofurong@ 123456caas.cn changhuiyun@ 123456caas.cn

Article

Publisher ID: S1567-5769(17)30335-1

DOI: 10.1016/j.intimp.2017.08.028

PMC ID: 7106160

PubMed ID: 28957693

SO-VID: b22e3536-392b-4f66-9c35-eda4e5ad6bd1

License:

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

History

Date received : 8 July 2017

Date revision received : 20 August 2017

Date accepted : 28 August 2017

Comments

Comment on this article

scite_

Cited by 23

See all cited by

Most referenced authors 1,061

See all reference authors

- Version 1
- Version 1

Interferon-omega: Current status in clinical applications

Read this article at

Abstract

Highlights

Related collections

Electrospinning for biomedical applications

Most cited references 92

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

IL-28, IL-29 and their class II cytokine receptor IL-28R.

Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Author and article information

Contributors

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 227

Cited by 23

Most referenced authors 1,061